PAVmed (NASDAQ:PAVM) released its earnings results on Sunday. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.06), MarketWatch Earnings reports.
Shares of PAVM opened at $5.55 on Tuesday. The stock has a market capitalization of $399.07 million, a P/E ratio of -7.30 and a beta of 0.13. The firm has a fifty day simple moving average of $2.59 and a two-hundred day simple moving average of $2.08. PAVmed has a twelve month low of $1.30 and a twelve month high of $5.63.
PAVM has been the subject of several analyst reports. Lake Street Capital upped their price target on shares of PAVmed from $5.00 to $9.00 and gave the company a “buy” rating in a research report on Monday. Ascendiant Capital Markets assumed coverage on PAVmed in a report on Thursday, November 5th. They set a “buy” rating and a $5.00 target price for the company.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Article: What does the Dogs of the Dow mean?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.